Last reviewed · How we verify
MORAb-009
At a glance
| Generic name | MORAb-009 |
|---|---|
| Sponsor | Morphotek |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma (PHASE2)
- Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) (PHASE2)
- Amatuximab for High Mesothelin Cancers (EARLY_PHASE1)
- A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers (PHASE1)
- A Study of MORAb-009 in Patients With Solid Tumor (PHASE1)
- An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer (PHASE2)
- A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MORAb-009 CI brief — competitive landscape report
- MORAb-009 updates RSS · CI watch RSS
- Morphotek portfolio CI